We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

78 hedge funds and large institutions have $50.5M invested in Cue Biopharma in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

428% more call options, than puts

Call options by funds: $586K | Put options by funds: $111K

156% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 9

123% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 13

24% more funds holding

Funds holding: 63 → 78 (+15)

17% more capital invested

Capital invested by funds: $43M → $50.5M (+$7.51M)

0.14% more ownership

Funds ownership: 0.93% → 1.07% (+0.14%)

Holders
78
Holders Change
+15
Holders Change %
+23.81%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
23
Reduced
9
Closed
13
Calls
$586K
Puts
$111K
Net Calls
+$475K
Net Calls Change
+$371K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$5.49M
2
State Street
State Street
Massachusetts
+$2M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.55M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.08M
5
Northern Trust
Northern Trust
Illinois
+$992K

Top Sellers

Rank Fund Capital Flow
1
PM
Prosight Management
Texas
-$4.11M
2
Millennium Management
Millennium Management
New York
-$653K
3
PAWC
P.A.W. Capital
Connecticut
-$536K
4
CC
Carlson Capital
Texas
-$470K
5
VC
Voss Capital
Texas
-$446K
Name Holding Trade Value Shares
Change 		Change in
Stake
SS
76
Sunbelt Securities
Texas
$865 – – –
AAG
77
Armstrong Advisory Group
Massachusetts
$438 – – –
Osaic Holdings
78
Osaic Holdings
Arizona
$273 – – –
PM
79
Prosight Management
Texas
– -$4.11M -38,395 Closed
PAWC
80
P.A.W. Capital
Connecticut
– -$536K -5,000 Closed
VC
81
Voss Capital
Texas
– -$446K -4,167 Closed
Parallax Volatility Advisers
82
Parallax Volatility Advisers
California
– -$268K -2,500 Closed
CSS
83
Cubist Systematic Strategies
Connecticut
– -$144K -1,344 Closed
Jane Street
84
Jane Street
New York
– -$96.3K -899 Closed
Squarepoint
85
Squarepoint
New York
– -$72.2K -674 Closed
Simplex Trading
86
Simplex Trading
Illinois
– -$45.4K -386 Closed
Group One Trading
87
Group One Trading
Illinois
– -$6.23K -53 Closed
PMEF
88
Point72 Middle East FZE
United Arab Emirates
– -$2.31K -22 Closed
AWM
89
Accel Wealth Management
Iowa
– -$1.14K -11 Closed
JMF
90
Johnson Midwest Financial
Iowa
– -$1.07K -10 Closed
ASN
91
Advisory Services Network
Georgia
– -$714 -7 Closed
1 2 3
4

CUE Hedge Fund Activity: Q2 2023 in Review

78 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q2 2023, worth a combined $50.5M — up 17% from $43M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new CUE positions and 13 closed out — a net gain of 16 holders — while 23 added to existing stakes and 9 trimmed.

The largest buyer was BlackRock, adding an estimated $5.49M. The largest seller was Prosight Management, exiting entirely with an estimated $4.11M sold.

  • 78 institutional investors held Cue Biopharma (CUE) as of Q2 2023, up from 63 in Q1 2023.
  • Funds reported $50.5M of Cue Biopharma stock for Q2 2023, up 17% quarter-over-quarter.
  • 29 funds opened new Cue Biopharma positions in Q2 2023 and 13 closed out, a net change of +16 holders.
  • The largest Cue Biopharma buyer in Q2 2023 was BlackRock, an estimated $5.49M added.
  • The largest Cue Biopharma seller in Q2 2023 was Prosight Management, an estimated $4.11M sold.

Based on aggregated 13F filings for Q2 2023.